Humacyte vs Prime Medicine
HUMA and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HUMA and PRME compare
Prime Medicine is the larger company, worth 4.7 times as much as Humacyte ($780M against $164M).
Prime Medicine scores higher on the StockData Score (5 against 2 for Humacyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HUMA | PRME |
|---|---|---|
| Size and price | ||
| Market cap | $164M | $780M |
| Share price | $0.592 | $4.30 |
| Change, 1 year | −56.2% | 22.0% |
| Change, 5 years | −94.6% | −79.6% |
| Beta (5Y) | 2.06 | 0.43 |
| Employees | 184 | 146 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 68.6× | – |
| P/B | 9.1× (better) | 19.6× |
| FCF yield | −53.9% | −20.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 52.5% | – |
| Revenue growth, 5Y average | – | −2.3% |
| Profitability | ||
| Gross margin | −475% | – |
| Operating margin | −4603% | – |
| Net margin | −3955% | – |
| FCF margin | −3697% | – |
| Return on equity | −1424% | −373% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −11.0× | – |
| Current ratio | 3.34 (better) | 3.05 |
| Altman Z-score | −10.29 | −5.56 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 26.4% | 58.8% |
| Held by insiders | 8.0% | 18.6% |
| Insider net buying, 12 months | $7.4K | – |
| Short interest, % of float | 11.0% | 19.7% |
Go deeper
- HUMA stock overview
- HUMA income statement
- HUMA valuation and score
- PRME stock overview
- PRME income statement
- PRME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.